Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage

Colorectal Cancer Clinical Trial

— FLUOCOL-1  

Official title:

Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage: a Single-blind Phase III Multicenter Randomized Controlled Trial (Intergroup FRENCH-GRECCAR Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05168839
• Other study ID #: 2021-582
• Status: Recruiting
• Phase: Phase 3
• Start date: September 26, 2022
• Est. completion date: October 31, 2025

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: Zaher Lakkis, MD, PhD
• Phone: +33.3.81.66.83.41
• Email: zlakkis[@]chu-besancon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC.

The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer.

The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or hand-sewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision.

A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited.

In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.

Description:

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC.

The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer.

The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or handsewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision.

The 26 participating centres are equipped with a scope with near-infrared (NIR) light source allowing real-time ICG perfusion assessment. The co-investigators are experienced digestive surgeons trained to work with and without IOFA. They have considerable experience in working together on research projects and have a proven track-record of efficacy. Moreover, this study will receive valuable support from the Surgery Research Network (FRENCH) and the Surgical Research on Rectal Cancer Group (GRECCAR), which have proved their ability to recruit patients into various multicentric studies and with which the FLUOCOL-1 project has been discussed.

The duration of participation for each patient is 90 days. The 3 study visits are superimposed to the schedule of standard of care (V1: pre-operation visit of selection and inclusion; Surgery; V2: 30-day post-operation visit and V3: 90-day post-operation visit).

The surgeon will do the 1:1 randomization between V1 and the day before surgery (D-30 to D-1). To reduce the risk of bias, patients will be blinded to the study group and the randomization will be stratified on participating centres, Body Mass Index (BMI), physical status classification score (=ASA score), preoperative treatment and tumor location. Patient will be assigned in the intervention (IOFA) or the control group (no IOFA).

At the exception of the information given on the study to the patient, the gathering of the written consent, the randomization and the HRQoL questionnaires, the patient will be treated following standard of care. Study data are the data systematically collected in the patient medical file except for the HRQoL questionnaires that will be collected under the supervision of a research technician financed by the study. The technician will capture the study data and the de-identified pdf version of the medical reports (consultations and hospitalizations) in the electronic Case Report Form (eCRF) after every visit.

A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited.

The ICG will be graciously provided by the manufacturer (SERB). An investigator meeting will be organized twice a year during the annual GRECCAR and FRENCH meetings. Newsletters will be sent every 3 months.

In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1010
• Est. completion date: October 31, 2025
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (age >18 years)

• Scheduled to undergo elective left colectomy or high rectal resection for cancer with intraperitoneal anastomosis.

• Signed consent

• Affiliated to the French social security system (CMU included).

Exclusion Criteria:

• Emergent surgery.

• Rectal cancer requiring total mesorectal excision and anastomosis below the peritoneal reflexion.

• Colon cancer requiring total or subtotal colectomy defined as a right colectomy extended to the splenic flexure or more).

• Colon cancer requiring transverse colectomy.

• Recurrent colorectal cancer.

• Locally advanced colorectal cancer requiring multi-visceral excision.

• History of colectomy.

• Associated concomitant resection of other organ (liver, etc.).

• Previous pelvic radiotherapy for pathology unrelated to diagnosis with colon cancer e.g. treatment for prostate cancer.

• Inflammatory bowel disease.

• History of known allergy to indocyanine.

• Pregnant patients.

• Refusal to participate or inability to provide informed consent.

• Protected adults (individuals under guardianship by court order).

Related Conditions & MeSH terms

• Anastomotic Leak
• Colorectal Cancer

Intervention

Drug:
• FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).
In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist. The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera. A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits. An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.

Locations

Country	Name	City	State
France	Centre Hospitalier Universitaire Amiens-Picardie	Amiens
France	CH Annecy	Annecy
France	Centre Hospitalier Universitaire de Besançon	Besançon
France	Centre Hospitalier Bourgoin-Jallieu	Bourgoin-Jallieu
France	Centre Georges François Leclerc	Dijon
France	University Hospital of Dijon	Dijon
France	Centre Hospitalier Universitaire de Grenoble	La Tronche
France	Centre Hospitalier Universitaire de Lille	Lille
France	Centre Hospitalier Lyon-Sud	Lyon
France	Centre lyonnais de chirurgie digestive	Lyon
France	Hôpiatl Européen	Marseille
France	Hôpital La Timone	Marseille
France	Hôpital Nord AP-HM	Marseille
France	Hôpital St Joseph Marseille	Marseille
France	Institut Paoli Calmettes	Marseille
France	CHU de Nancy	Nancy
France	Hôpital Bicêtre	Paris
France	Hôpital Cochin	Paris
France	Hôpital Européen Georges Pompidou	Paris
France	Hôpital Saint Antoine	Paris
France	Hôpital Saint Louis	Paris
France	Centre Hospitalier de Pontoise	Pontoise
France	Hôpital Robert Debré	Reims
France	Ch Pontchaillou	Rennes
France	Centre Hospitalier Universitaire de Rouen	Rouen
France	Santé Atlantique	Saint-Herblain
France	Centre Hospitalier Universitaire de Strasbourg	Strasbourg
France	CHU de Toulouse	Toulouse
France	Clinique TIVOLI	Toulouse
France	Centre Hospitalier de Tours	Tours
France	Institut cancérologie de Lorraine	vandoeuvre les Nancy
France	Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

References & Publications (1)

Wojcik M, Doussot A, Manfredelli S, Duclos C, Paquette B, Turco C, Heyd B, Lakkis Z. Intra-operative fluorescence angiography is reproducible and reduces the rate of anastomotic leak after colorectal resection for cancer: a prospective case-matched study. Colorectal Dis. 2020 Oct;22(10):1263-1270. doi: 10.1111/codi.15076. Epub 2020 May 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anastomotic leakage 90 days after surgery	The primary outcome is the occurence of an anastomotic leakage during the 90 days following surgery.; Anastomotic leakage is defined as any clinical signs of leakage diagnosed by radiological examination or surgical exploration, or as any isolated pelvic organ infection without leakage evidence, as defined by the International Rectal Cancer Study Group.	90 days after surgery
Secondary	Change in planned anastomotic site.	Change in planned anastomosis during surgery is defined as any decision change on perfusion assessment such as modifying the initially planned transection level of the descending colon or refashioning anastomosis including the decision to undertake a permanent stoma rather than an anastomosis.	During surgery
Secondary	Rate of patients with a defunctioning stoma.	The rate of defunctioning stoma created in the initial surgery as a temporary diverting pathway will be calculated.	Surgery time.
Secondary	Overall 30-day postoperative morbidity.	Overall 30-day postoperative morbidity is defined and classified according to the Clavien-Dindo classification.	30 days after surgery.
Secondary	Overall 90-day postoperative morbidity.	Overall 90-day postoperative morbidity is defined and classified according to the Clavien-Dindo classification.	90 days after surgery.
Secondary	Mortality rate.	90-day postoperative mortality.	90 days after surgery.
Secondary	Hospital length of stay.	Postoperative length of hospital stay.	End of hospital stay.
Secondary	Postoperative reintervention.	Postoperative reintervention number and type within 90 days.	90 days after surgery.
Secondary	Quality of life assessment.	Health related quality of life is assessed using the quality of life questionnaires : QLQ-C30 and QLQ-CR29 at baseline and 90 days post-operation.; The QLQ-C30 is a patient self-rating questionnaire (30 questions) that measures physical, role, social, emotional, and cognitive functions as well as overall QoL. Scores can be linearly transformed to provide a score from 0 to 100 REF. Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.; The QLQ-CR29 (Quality of life of rectal cancer patients with 29 questions) has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items. The score can range from 0 to 100.; Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.	90 days after surgery.
Secondary	Medico-economic analysis	The medico-economic analysis takes into consideration health care costs up until 90 days post-operation.	90 days after surgery.